STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Why only for healthcare professionals?

The content on these information pages is directed solely at you if you are a doctor, nurse, or pharmacist, as it concerns treatment with prescription medicines.

Please confirm that you are a healthcare professional (healthcare assistant, nurse, doctor, psychologist, or other licensed healthcare professional).

Back to main page

Confirm and continue

News
September 4, 2025

Entertainment Daily: Gemma Collins weight loss with Yazen programme

Gemma Collins has unveiled her stunning weight loss, crediting Yazen’s GLP-1 programme and injections for helping her feel healthier, happier, and free from dieting struggles.

Gemma Collins reveals weight loss transformation with Yazen

Reality star Gemma Collins has shared her dramatic two dress size drop, revealing that GLP-1 weight-loss injections prescribed by Yazen have “absolutely changed her life.” In a candid Instagram video, Gemma explained how the injections helped her feel “healthier and happier” after years of struggling with her weight.

Despite some concerns from fans about potential side effects, the majority showed support for Gemma’s transparency and celebrated her new journey to better health.

Read the full story at Entertainment Daily.

More news

WOD26: Data Reveals Persistent Shame & Stigma Around Obesity Treatment

Ahead of World Obesity Day on 4 March, Yazen is sharing new findings from internal patient data, revealing that shame and stigma remain major barriers to obesity care — even as effective medical treatments become more widely available.

UK firms eye GLP-1 benefits to cut sick leave and boost performance.

UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.

Yazen achieved record-breaking growth in 2025, doubling its revenue.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.